U.S. FDA Fast-Tracks Nektar Therapeutics’ Rezpegaldesleukin for Severe-to-Very-Severe AA
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Nektar Therapeutics’ rezpegaldesleukin for the treatment of severe-to-very-severe alopecia areata (AA) in adults and pediatric patients aged 12 and older who weigh at least 40 kilograms.